請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23598
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林能白(Neng-Pai Lin) | |
dc.contributor.author | Hui-Erh Liu | en |
dc.contributor.author | 劉惠娥 | zh_TW |
dc.date.accessioned | 2021-06-08T05:04:30Z | - |
dc.date.copyright | 2011-03-03 | |
dc.date.issued | 2011 | |
dc.date.submitted | 2011-01-28 | |
dc.identifier.citation | 英文文獻
Aaker, D.A.(1989)'Managing Assets and Skills : The Key to a Sustainable Competitive Advantage' California Management Review, Winter , pp.91-106. Chien IC, Chou YJ, Lin CH, Bih SH, Chou P, Chang HJ.(2004). Prevalence and incidence of schizophrenia among national health insurance enrollees in Taiwan, 1996-2001. Psychiatry Clin Neurosci;58(6):611-8. Bearden, W.O, Ingram, T.N. & Laforge, R.W.(1995).Marketing :Principle & Perspectives.(Homewood,IL:Richard D. Irwin). Berman, Barry & Evans J.R.,(1978) .Retail Management: A Strategic Approach.New York:Macmillan Publishing Co. Inc., p125. Collis & Montgomery(1995).Competing on Resource: Strategy in The 1990s. Harvard Business Review. 73(4), pp.118-128. Jay Barney(1991). Firm resources and sustained competitive advantage,Journal of Management, Vol. 17, No. 1, pp. 99-120. Jay Barney & William Hesterly (2006). Strategic management and competitive advantage, concepts 2nd ed. Prentice-Hall,Upper Saddle River. New Jersey. Kapur S & Remington G(2000). Atypical antipsychotics: patients value the lower incidence of extrapyramidal side effects. British Medical Journal; 321: 1360-1361. Knapp M.(1997) Costs of schizophrenia. The British Journal of Psychiatry; 171:509-518 Koda-Kimble MA, Young LY, Kradjan WA, Alldredge BK, Corelli RL(2005). Applied Therapeutics: The Clinical Use of Drugs. Eighth Edition. Lippincott Williams & Wilkins Knapp M.(1997) Costs of schizophrenia. The British Journal of Psychiatry, 171:509-518. Kupfer DJ, Sartorius N.(2002)The Usefulness and Use of Second-Generation Antipsychotic Medications. Current Opinion in Psychiatry;15(Supplement 1):S1-S51. Lehman AF, Lieberman JA(2004). Practice guideline for treatment of patients with schizophrenia In. 2ed: American psychiatric Association. Leucht S, Barnes TR, kissling W, Engel RR, Correll C, Kane JM.(2003).Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry; 160(7):1209-22. Philp Kotler(1998).Marketing Management Analysis Planning ,Tenth Edition Planning,Vol.31,No.3,pp. 481-487.Prentice Hall Inc.New Jersey. Philp Kotler(2000).Marketing Management. Prentice-Hall, Upper Saddle River, New Jersey. Porter, M. E. (1980).Competitive Strategy: Techniques for Analyzing Industries and Competition. Free Press, New York, NY. Porter, M. E.(1985). Competitive Advantage: Creating and Sustaining Superior Performance, Free Press, New York, NY. Maynard A, Bloor K(1998). Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals. The British Journal of Psychiatry, 173: 12-18. Mueser KT, McGurk SR(2004). Schizophrenia. Lancet;363(9426):2063-72. Michael A. Hitt、R. Duane Ireland & Robert E. Hoskisson (1999) .Strategic Management - Competitiveness and Globalization . Rabiner CJ, Wegner JT, Kane JM. Outcome study of first-episode psychosis. I: Relapse rates after 1 year. Am J Psychiatry 1986; 143(9):1155-8. Stahl SM.(2001)Psychosis and Schizophrenia. In: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Second ed;:365-99. Walburn J, Gray R, Gournay K, Quraishi S, david AS(2001). Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry;179:300-7. Warner R, de Firolamo G.(1995)Epidemiology of Mental Disorders and Psychosocial Prolblems: Schizophrenia. World Health Organization. Wernerfelt, B. (1989).Form Critical Resource to Corporate Strategy. Journal of General Management ,Vol.14, pp.4-12. Grant, R.M.(1990).The Nature and Basis of Competitive Advantage: A Dynamic Approach. The Tenth Annual Strategic Management Society Conference, Stockholm, pp.1-18. Grant, R.M.(1991).The Resource-based Theory of Competitive Advantage: Implications for Strategy Formulation. California Management Review, Vol.33 Iss.3, pp.114-135 Grant, R.M.(1991).Contemporary Strategy Analysis: concepts,techniques,Applications,pp.93-121. Prahalad & Hamel(1990).The Core Competence of the Corporation. Harvard Business Review, May-June, pp.277-299 . Hall, R.(1992).The Strategic Analysis of Intangible Resource. Strategic Management Journal. Vol.13 Iss.2, pp.135-144 Robert K. Yin (1994) .Case Study Research: Design and Method. Thousand Oaks, CA: Sage Publications, pp.80-118. 中文文獻 黃俊英、陳世穎 (2003)。市場基礎資產之角色:資源基礎理論觀點。開南管理學院。運籌研究期刊 ,6(3),p43-60。 程 馨(2004)。全民健保藥品政策與藥品費用成長趨勢分析。長庚大學醫管所碩士論文。 沈武典(2004)。21世紀臨床神藥物學。修訂版: 合計書局。 洪家偉(2004)。抗精神病藥物於精神分裂症患者之使用評估。成功大學臨床藥學研究所碩士論文。 李逸鴻(2005)。藥物經濟學在醫院藥品選擇的應用:以非典型抗精神病藥物為例。高雄醫學大學碩士論文。 馮偉明(2006)。以資源基礎觀點探討台灣IC設計產業關鍵成功因素。國立中山大學碩士論文。 陳錫銘(2008)。臺灣醫療旅遊產業創新服務之策略研究。國立交通大學碩士論文。 曾煥井(2009)。牙醫醫療產業加盟連鎖營運之競爭策略研究-以D牙醫集團為例。輔大碩士論文。 周文賢(1999)。行銷管理--市場分析與策略規劃,台北:智勝文化事業有限公司。 蔡敦浩(1994)。高雄地區建築業的資源基礎觀點之研究。台北:行政院國家科學委員會。 榮泰生(1997)。行銷管理學。台北:五南 。 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/23598 | - |
dc.description.abstract | 根據IMS Data及全勝藥品健保資料庫之統計資料,台灣目前第二代抗精神病劑(Second generation anti-psychotics,簡稱SGA)市場占率前兩大藥物,分別為1997年在台上市的藥品(本研究稱A藥)及2000年在台上市的藥品(本研究稱B藥)。並且發現後進入市場初期銷售不理想的B藥,現在已成為市占第一大藥品,引發想瞭解其中差異性與關鍵性因素為何?A、B藥的行銷策略為何?所採取的行銷策略與其兩家企業擁有的資源與能力有何關係?因此,本研究目的,欲探討台灣兩大第二代抗精神病劑企業如何運用資源與能力來影響其行銷策略。
本研究為定性分析之描述性個案研究,主要以企業資源特性與行銷策略討論為研究架構。藉由IMS Data及全勝藥品健保資料庫統計之資料分析、透過文獻探討,瞭解精神疾病及用藥、行銷策略、資源基礎理論及其策略如何受其公司資源與能力的影響,並以個案研究方式進行。 本研究經過次級資料的收集與相關文獻的佐證後,根據研究架構,逐步研討A藥與B藥的行銷策略及其企業的資源與能力,進行相關資料分析與評估後;發現B藥以初期弱勢之態勢,最後竟然反敗為勝成為市場領導著的原因,主要是B藥運用企業本身的資源能力配合靈活的市場因應策略。基本上,A藥及B藥皆善用本身的資源能力建構出成功的差異化策略;但最終,兩者要持續成功必須考慮調整策略或行銷組合。 | zh_TW |
dc.description.abstract | According IMS data and National Data Consultant data base, the top two anti-psychotics are A drug and B drug. Although B drug did not seem to perform well at the beginning of its launch, it became the market leader eventually. We were interested in knowing the marketing strategies, and the correlation between companies’ resources and their strategies. Therefore, the purpose of this study was to analyze the adopted strategies, resources, and capabilities of these two companies. And then discussed the relationship between companies’ resources and their marketing strategies for A and B drug.
The methods of this study included qualitative analysis and descriptive case study. Two major elements of study structure are marketing strategy and resource of enterprise. Based on the analyses of IMS data and BNHI data base, we conducted the case study of two anti-psychotics. Through reviewing relative literature, we aimed at understanding the psychiatry disease and medication, marketing strategy, and resource-based theory. This study used secondary data collection and literature review to conduct the case study of two targeted antipsychotics. It was found that the reason why B drug became the market leader is because of his flexible marketing strategies. Basically, both anti-psychotic A and B were able to utilize their own resources and capabilities to construct their own differentiation strategy successfully. However, if these two companies want to sustain their initial success, adjustment of the strategies and marketing mix according the evolution of market and competition is required. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T05:04:30Z (GMT). No. of bitstreams: 1 ntu-100-P95843015-1.pdf: 827039 bytes, checksum: 8e4eb1f45a08fecaa896ba89d066f8bc (MD5) Previous issue date: 2011 | en |
dc.description.tableofcontents | 口試委員審定書 I
誌謝 II 中文摘要 III Abstract IV 第一章 緒論 1 第一節、研究背景與動機 1 第二節、研究目的 6 第三節、研究流程 6 第二章 文獻探討 8 第一節、精神分裂症介紹、流行病學和治療 8 第二節、第二代抗精神病劑用藥的沿革與現況 10 第三節、行銷策略相關文獻 11 第四節、資源基礎理論 17 第五節、資源基礎理論與策略之關係 19 第三章 研究方法 23 第一節、研究架構 23 第二節、研究設計 26 第四章 研究結果 28 第一節、個案分析—A藥 28 第二節、個案分析—B藥 33 第三節、以4P的觀點進行A藥與B藥差異性比較 38 第四節、A藥公司與B藥公司的資源基礎分析 46 第五章 討論 49 第一節、A藥公司內部資源與能力及行銷策略之分析 49 第二節、B藥公司內部資源與能力及行銷策略之分析 53 第三節、行銷策略與資源的關係 58 第六章 結論與建議 60 第一節、結論 60 第二節、研究限制 64 第三節、建議 65 參考文獻 67 英文文獻 67 中文文獻 70 表目錄 表1-1-1 台灣歷年健保藥費 1 表1-1-2 2008年國人十大健保用藥給付金額排行 2 表2-1-1 精神分裂症五大臨床表徵 9 表2-4-1 Porter競爭優勢矩陣表 16 表4-1-1 A藥抗精神病劑健保給付價 31 表4-2-1 B藥抗精神病劑健保給付價 35 表4-3-1 A藥與B藥之產品比較 38 表4-3-2 A藥與B藥之價格比較 41 表4-3-3 A藥與B藥之通路比較 43 表4-3-4 A藥與B藥之推廣面比較 44 表4-4-1 A藥公司的基礎資源分析(就A藥的角度) 47 表4-4-2 B藥公司的基礎資源分析(就B藥的角度) 47 表5-1-1 A藥主要行銷策略 50 表5-1-2 A藥公司資源與能力所對應之行銷策略 51 表5-2-1 B藥主要之行銷策略 54 表5-2-2 B藥公司資源與能力所對應之行銷策略 55 表6-1-1 A藥與B藥之BCG矩陣與產品佈局思考 63 圖目錄 圖1-1-1 第二代抗精神病劑健保給付金額(1998~2008) 1 圖1-1-2 台灣1998年到2008年各第二代抗精神病劑藥費金額圖 3 圖1-1-3 A藥與B藥在台灣地區前三大科別的用藥相對百分比圖 4 圖1-3-4 研究流程圖 7 圖2-4-1 Barney(1991)資源特性與競爭優勢間之關係 19 圖3-1-1 公司內部資源與能力所需考量的因素圖 25 圖3-1-2 研究架構圖 25 圖4-4-1 A藥公司於主力產品競爭的策略發展模式 48 圖4-4-2 B藥公司於產品競爭的策略發展模式 49 | |
dc.language.iso | zh-TW | |
dc.title | 台灣藥品行銷策略之初探-以第二代抗精神病劑為例 | zh_TW |
dc.title | A Primary Research of Pharmaceutical Marketing Strategy–A Case Study of Second Generation Anti-Psychotics | en |
dc.type | Thesis | |
dc.date.schoolyear | 99-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 黃玉書(Yu-Shu Huang),陳基旺(Ji-Wang Chern) | |
dc.subject.keyword | 資源基礎理論,競爭策略,競爭優勢,精神科用藥,藥品行銷,藥品市場, | zh_TW |
dc.subject.keyword | Anti-Psychotics,Competitive advantage,Competitive Strategy,Pharmaceutical market,Pharmaceutical marketing strategy,Resource-based theory, | en |
dc.relation.page | 70 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2011-01-28 | |
dc.contributor.author-college | 公共衛生學院 | zh_TW |
dc.contributor.author-dept | 健康政策與管理研究所 | zh_TW |
顯示於系所單位: | 健康政策與管理研究所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-100-1.pdf 目前未授權公開取用 | 807.66 kB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。